Recombinant Human Ube2H protein

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Ubiquitin-conjugating enzyme E2 H (Ube2H) also known as UBC8 is an enzyme that functions mechanically to facilitate the transfer of ubiquitin to substrate proteins a process essential for regulating protein degradation. Ube2H weighs approximately 20 kDa and shows expression in various tissues especially in the liver and skeletal muscle. It belongs to the E2 ubiquitin-conjugating enzyme family which plays an important role in the ubiquitin-proteasome pathway.

Biological function summary

Ubiquitin-conjugating enzyme E2 H plays a central role in protein homeostasis by tagging proteins for proteasomal degradation. It does not function alone but as part of larger complexes that include E1 activating enzymes and E3 ubiquitin ligases. These complexes work in synchrony to ensure precise ubiquitination of target proteins which helps regulate multiple cellular processes such as cell cycle progression DNA repair and immune response.

Pathways

Ubiquitin-conjugating enzyme E2 H integrates with several critical cellular pathways including the ubiquitin-proteasome pathway and the DNA damage response pathway. In the ubiquitin-proteasome pathway Ube2H works alongside other E2 enzymes like Ube2C to assist in the ubiquitination process. It has a notable connection with proteins like p53 and BRCA1 which are vital in maintaining genomic stability and tumor suppression.

Ubiquitin-conjugating enzyme E2 H has recognized implications in cancer and neurodegenerative diseases. Aberrations in its function can lead to improper protein degradation contributing to the accumulation of defective proteins that can cause cellular dysfunction. In cancer Ube2H is often linked with anomalies in the ubiquitin-proteasome system affecting the degradation of oncogenic proteins. Additionally its interaction with p53 a protein known for its tumor suppressor functions highlights its potential involvement in cancer progression when dysregulated.